- Home
- HTO vs BCRX Comparison
HTO vs BCRX Comparison
Compare HTO & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | BCRX |
|---|---|---|
| Founded | 1985 | 1986 |
| Country | United States | United States |
| Employees | 837 | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | HTO | BCRX |
|---|---|---|
| Price | $61.77 | $10.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $62.00 | $20.82 |
| AVG Volume (30 Days) | 457.3K | ★ 6.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | $12.55 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.75 | $6.00 |
| 52 Week High | $62.68 | $10.94 |
Technical Indicators
Market Signals| Indicator | HTO | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 69.36 |
| Support Level | $55.76 | $8.13 |
| Resistance Level | $61.87 | $10.94 |
| Average True Range (ATR) | 1.35 | 0.57 |
| MACD | 0.41 | 0.13 |
| Stochastic Oscillator | 80.08 | 93.71 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.